Energenesis Biomedical Partners with Yoo Young Pharm for ENERGI-F703DFU in Korea

TAIPEI, Oct. 5, 2026 /CourierPR/ -- Energenesis Biomedical Co., Ltd. (TWSE: 6657) has entered into a strategic partnership with Yoo Young Pharm. Co., Ltd. to explore the development, registration, and commercialization of ENERGI-F703DFU in the Korean market. This collaboration aims to leverage Energenesis' extensive data package, including Phase III clinical trial data, and Yoo Young Pharm's robust commercial and clinical network in the region.

ENERGI-F703DFU is an investigational topical small-molecule gel designed to promote healing of diabetic foot ulcers by modulating cellular energy pathways. The drug candidate is intended to increase intracellular ATP levels at the wound site, supporting epithelial cell migration and activating intrinsic repair mechanisms. According to a post-hoc analysis of the Phase II study (NCT02672436), patients meeting the current Phase III eligibility criteria achieved complete wound closure rates of 36.7% with ENERGI-F703DFU compared to 9.1% with vehicle control over a 12-week treatment period (P<0.05).

Energenesis Biomedical Co., Ltd. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics that restore cellular energy and activate intrinsic repair mechanisms. The company combines proprietary small-molecule innovation with AI-driven drug repurposing to address significant unmet medical needs across multiple therapeutic areas, including chronic wounds, neurodegenerative diseases, and rare disorders.

Yoo Young Pharm. Co., Ltd., established in 1981, is a fully integrated South Korean pharmaceutical company with comprehensive capabilities spanning in-house R&D, global cGMP-compliant manufacturing (PIC/S, PMDA), and commercialization. The company leverages established leadership in musculoskeletal care, metabolic diseases, and tissue regeneration to advance innovative therapeutics and deliver high-quality healthcare solutions across domestic and global markets.

Under the terms of the Memorandum of Understanding (MOU), the parties intend to work toward a definitive agreement under which Yoo Young Pharm. Co., Ltd. would receive rights to develop, register, and commercialize ENERGI-F703DFU in Korea. The MOU establishes the framework for continued discussions, with terms of any definitive agreement remaining subject to further negotiation between the parties.